IceCure Medical Ltd., developer of minimally-invasive cryoablation technology, the ProSense System, that destroys tumors by freezing as an alternative to surgical tumor removal, announced that interim data from the ICE3 Clinical Trial on cryoablation of small, low-risk breast cancer was featured by Co-Primary Investigator Kenneth Tomkovich, M.D., at RSNA 2021.

December 7, 2021 — IceCure Medical Ltd., developer of minimally-invasive cryoablation technology, the ProSense System, that destroys tumors by freezing as an alternative to surgical tumor removal, announced that interim data from the ICE3 Clinical Trial on cryoablation of small, low-risk breast cancer was featured by Co-Primary Investigator Kenneth Tomkovich, M.D., at RSNA 2021.

Tomkovich's presentation, "Primary Treatment of Low Risk Breast Cancers Using Image-Guided Cryoablation: A 6 Year Update of the ICE3 Trial" was selected to be featured in a daily bulletin by RSNA, the largest radiology society in the world with over 48,000 members in the U.S., representing 31 radiologic sub-specialties sharing state-of-the-art radiological innovations.

Tomkovich featured the ICE3 interim results on Nov. 30 as part of the larger "Breast Imaging (Breast Intervention and PET/Breast Imaging in Neoadjuvant Chemotherapy" session.

Eyal Shamir, chief executive officer of IceCure, noted, "We are proud that our data was recognized by RSNA, the largest radiology society in the world and a highly regarded medical association. We believe this recognition by this prestigious society is further supportive of the ICE3 data."

Tomkovich commented, "The acceptance of cryoablation as a treatment for breast cancer is becoming more wide-spread in the radiological medical community and the interim ICE3 trial results continue to validate this approach. It is an option that could be much more convenient than a mastectomy or lumpectomy surgery, in terms of requiring less office time, as well as less stress and a quick recovery for the patient."

For more information: icecure-medical.com

Related RSNA2021 content

Related Content

Sponsored Content | Videos | Magnetic Resonance Imaging (MRI)

With the recent launch of the Magnifico Open, Italian company Esaote has entered the open MRI whole body space. ITN had ...

Time January 24, 2022
arrow
Feature | Breast Imaging | By Bhvita Jani

The rising global incidence rates of breast cancer, coupled with the severe backlog of women requiring breast cancer ...

Time January 20, 2022
arrow
Feature | Vendor Neutral Archive (VNA)

Vendor neutral archives (VNAs) have become a staple within the healthcare IT system. At the Radiological Society of ...

Time January 20, 2022
arrow
Feature | Radiology Business | By Jef Williams

The Great Resignation has impacted every industry, including ours. While this movement will be studied for years to come ...

Time January 20, 2022
arrow
Sponsored Content | Case Study | Ultrasound Imaging

The most common cause of chronic liver disease? Nonalcoholic fatty liver disease (NAFLD). With 25% of the world’s ...

Time January 19, 2022
arrow
News | Women's Health

January 18, 2022 — The following statement was issued today by the U.S. Food and Drug Administration (FDA), and is ...

Time January 18, 2022
arrow
News | Breast Imaging

January 18, 2022 — UE LifeSciences has entered into a definitive distribution agreement with Siemens Healthineers ...

Time January 18, 2022
arrow
News | Ultrasound Women's Health

January 17, 2022 — According to an article in ARRS’ American Journal of Roentgenology (AJR), radiologists should ...

Time January 17, 2022
arrow
News | Mammography

January 14, 2022 — Computer engineers and radiologists at Duke University have developed an artificial intelligence ...

Time January 14, 2022
arrow
Videos | Artificial Intelligence

Here are two examples of artificial intelligence (AI) driven pulmonary embolism (PE) response team apps featured by ...

Time January 13, 2022
arrow
Subscribe Now